Valuation: Amgen Inc.

Market Cap 230B 204B 190B 172B 323B 21,764B 328B 2,274B 893B 11,389B 862B 844B 36,333B P/E 2026 *
27x
P/E 2027 * 24.1x
Enterprise Value 271B 241B 224B 203B 381B 25,681B 387B 2,683B 1,054B 13,439B 1,017B 996B 42,874B EV / Sales 2026 *
6.96x
EV / Sales 2027 * 6.57x
Free-Float
99.77%
Yield 2026 *
2.37%
Yield 2027 * 2.51%
1 day+1.26%
1 week+5.31%
Current month+3.05%
1 month+10.42%
3 months+18.89%
6 months+22.85%
Current year+29.23%
1 week 31.5
Extreme 31.5
32.53
1 month 28.41
Extreme 28.41
32.53
Current year 23.95
Extreme 23.95
32.94
1 year 23.95
Extreme 23.95
32.94
3 years 23.95
Extreme 23.95
32.94
5 years 23.95
Extreme 23.95
32.94
10 years 23.95
Extreme 23.95
32.94
Manager TitleAgeSince
Chief Executive Officer 63 01/05/2012
Director of Finance/CFO 62 13/05/2010
Chief Tech/Sci/R&D Officer 57 01/06/2023
Director TitleAgeSince
Chairman 63 01/01/2013
Director/Board Member 65 01/01/2012
Director/Board Member 71 01/01/2012
Change 5-day change 1-year change 3-year change Capi.($)
+1.26%+5.31% - - 230B
+4.04%+10.19%+58.90%+119.86% 1,106B
+2.30%+4.34%+33.91%+69.55% 612B
+2.70%+5.29%+24.48%+97.54% 500B
+2.58%+8.31%+37.43%+63.51% 367B
+4.49%+4.42%+71.76%+44.40% 354B
+1.85%+5.45%+21.38%+49.26% 286B
+1.76%+4.92%+0.48%+20.31% 256B
+3.94%+6.27%+44.64%+57.36% 230B
+2.25%+5.75%+27.06%+101.05% 190B
Average +2.65%+2.13%+35.56%+69.21% 433.35B
Weighted average by Cap. +2.94%+2.30%+40.74%+80.64%

Financials

2026 *2027 *
Net sales 38.97B 34.68B 32.14B 29.13B 54.74B 3,691B 55.66B 386B 152B 1,932B 146B 143B 6,162B 40.36B 35.92B 33.29B 30.17B 56.69B 3,823B 57.64B 399B 157B 2,001B 151B 148B 6,382B
Net income 8.54B 7.6B 7.05B 6.38B 12B 809B 12.2B 84.54B 33.21B 423B 32.03B 31.37B 1,351B 9.43B 8.39B 7.78B 7.05B 13.24B 893B 13.46B 93.3B 36.65B 467B 35.36B 34.62B 1,491B
Net Debt 41.36B 36.81B 34.12B 30.92B 58.1B 3,918B 59.07B 409B 161B 2,050B 155B 152B 6,541B 35.3B 31.42B 29.12B 26.39B 49.6B 3,344B 50.43B 349B 137B 1,750B 132B 130B 5,583B
Projected Income Statement - Annual - Amgen Inc.
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
20/10/26 CA$32.10 +1.26% 716
19/10/26 CA$31.70 -0.63% 1,430
16/10/26 CA$31.90 -1.60% 1,772
15/10/26 CA$32.42 +6.36% 11,160
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Amgen Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
424.94USD
Average target price
394.98USD
Spread / Average Target
-7.05%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amgen Inc.